Advanced Courses

ESMO-ESO Courses on Medical Oncology for Medical Students

These annual five-day residential courses enable students to get a full picture of this challenging and interesting professional field before making the choice of their specialisation.

Preceptorship Courses

Apply now to join one of our Preceptorship courses!

Workshops & Courses

ESMO fosters the advancement of cancer research by supporting clinical trials workshops to inspire young oncologists from different disciplines across the globe to become the next generation of active researchers.

Patient Guides

Guides for Patients are designed to assist patients, their relatives and caregivers to better understand the nature of different types of cancer and evaluate the best available treatment choices

Personalised Medicine Explained

Video interviews and articles designed to help patients, policy makers and other non-medical professionals better understand the principles of personalised cancer medicine

Getting the Most out of Your Oncologist

Now available in Romanian, our Guide for Patients with Advanced Cancer is designed for patients, their family members and oncologists.

Designated Centres of Integrated Oncology and Palliative Care

The ESMO Designated Centres of Integrated Oncology and Palliative Care accreditation programme recognises cancer centres which provide comprehensive services in supportive and palliative care as part of their routine care.

EFPIA Disclosure Code

Policy News

Welcome to OncologyPRO, the home of ESMO’s educational and scientific resources, with Guidelines, a comprehensive list of E-Learning modules, Factsheets on biomarkers, slides and webcasts from our educational programme, and more... to support continuing medical education and daily practice!

Pembrolizumab is intended as a monotherapy for the treatment of unresectable or metastatic melanoma in adults

On 21 May 2015, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product pembrolizumab (Keytruda), intended as monotherapy for the treatment of advanced (unresectable or metastatic) melanoma in adults.

The applicant for this medicinal product is Merck Sharp & Dohme Limited.

Pembrolizumab will be available as a 50 mg powder for concentrate for solution for infusion.

The active substance of Keytruda is pembrolizumab, an antineoplastic monoclonal antibody (ATC code L01XC18) that potentiates T cell responses, including anti-tumour responses, through blockade of PD-1 binding to PD-L1 and PD-L2 ligands.

The CHMP based its recommendation on one uncontrolled study and on early results from two ongoing randomised controlled trials (one comparing pembrolizumab with standard chemotherapy and the other comparing pembrolizumab with ipilimumab). The Committee considered that the studies demonstrate the efficacy of pembrolizumab, both in patients who had not previously received ipilimumab and in patients who had previously received ipilimumab.

The most common side effects are diarrhoea, nausea, pruritus, rash, arthralgia and fatigue. Pembrolizumab is associated with immune-related adverse reactions including pneumonitis, colitis, hepatitis, nephritis, endocrinopathies, uveitis, myositis, pancreatitis, and severe skin reactions.

The full indication is: "Keytruda as monotherapy is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults".

It is proposed that pembrolizumab be prescribed by physicians experienced in the treatment of cancer.

Detailed recommendations for the use of this product will be described in the summary of product characteristics, which will be published in the European public assessment report and made available in all official European Union languages after the marketing authorisation has been granted by the European Commission.

The opinion adopted by the CHMP is an intermediary step on pembrolizumab’s path to patient access. The CHMP opinion will now be sent to the European Commission for the adoption of a decision on an EU-wide marketing authorisation. Once a marketing authorisation has been granted, each Member State will take a decision on price and reimbursement based on the potential role/use of this medicine in the context of its national health system.